Melanoma

Resectable
Stage III-IV

Neoadjuvant /Adjuvant

ECOG-ACRIN-S1801
Phase II Adjuvant vs NeoAdjuvant MK-3475 (Pembrolizumab) in Stage III-IV High-Risk Melanoma

PI: Reddy
ECOG ACRIN

Unresectable
Stage III-IV

Any Line

Previously treated with PD-1

CCT5055
A Phase II, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma (Instil Bio Study ITIL-168-101)

PI: Instil Bio
Bristol Myers Squibb

KEY: Pending, Open for Enrollment, Optional Path, Extension Study, Immunotherapy, Trial Posting, Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu